Biocryst Pharmaceuticals Inc (BCRX) Hedge Fund & Institutional Holdings (Q2 2026)

BCRX ranks #1983 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

320 institutions disclose a position in BCRX, but none treat it as a major bet — even TCG Crossover Management, LLC, its most concentrated holder, allocates just 2.6% of its own portfolio to it.

Assenagon Asset Management S.A. has added to its BCRX position for two straight quarters, increasing it by $1.5M to reach $3.7M today.

Essential Partners LLC has trimmed its BCRX position for two straight quarters, cutting it by $30.1K while still holding $6.9K.

BCRX is down 2.9% today, but institutions show net buying of $288.8M this quarter — a divergence between today's price move and the underlying institutional flow.

BCRX reported a net loss of $384.7M over the trailing twelve months.

• Not yet profitable — net loss of $384.7M over the trailing twelve months
• Revenue declined 4.4% year over year
• Net income declined year over year, from -$35.7M to -$384.7M
• Generated $347.4M in positive operating cash flow
• Current ratio of 2.06x — enough short-term assets to cover short-term liabilities